How Policies Shape the Rare Disease Treatment Landscape
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts explore policies shaping rare disease drug development and access.
Newest Standards of Care Continue to Reflect Advances in Diabetes Technology
Continued emphasis on diabetes management technology and patient-centered care in updated clinical management standards highlight the importance of advancing quality measurement.
Medicare Nebulizer Use for COPD Differs by Race/Ethnicity
Rates of filled prescriptions for nebulizers in Medicare FFS vary across factors such as age, disability, and race/ethnicity.
How the FDA and Market Access Impact Rare Disease Drug Access
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into access drivers and considerations in the rare disease space.
Innovations in Patient-Centricity: How Rare Disease is Leading the Way
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into patient centricity trends in rare disease.
Decoding the CY 2025 Advance Notice
Join Avalere’s healthcare policy experts as they dissect the Advance Notice of Methodological Changes for CY 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies and discuss the future trajectory of Medicare Advantage (MA) in Part D and potential outcomes, headwinds, and tailwinds for health plans.
How to Think About Rare Diseases in the US and Globally
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts provide an introduction into regulatory approaches to rare diseases.
Status of US Prescription Drug Importation Pathways
Recent FDA authorization of Florida’s Section 804 Importation Program has prompted increased focus on importation pathways.
Quantifying Indirect Burden and Measuring Novel Elements of Value
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #10: Quantifying Indirect Burden and Measuring Novel Elements of Value
Impacts of Inflation Reduction Act on Patient Behavior and Affordability
Avalere experts are joined by Kevin L. Hagan, President of the PAN Foundation, to discuss their findings on the impacts of the Inflation Reduction Act’s Part D benefit redesign on patient utilization and affordability.
Policy’s Pressure on HEOR
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #9: Policy’s Pressure on HEOR.
HEOR as a Differentiator Versus a Commodity
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #8: HEOR as a Differentiator Versus a Commodity.
Reevaluating Value Assessment for HEOR in 2023
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #7: Value Assessment.
Contextualizing AI for HEOR in 2023
In this installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #6: Artificial Intelligence.
Embedding Patient-Centric Principles in Research, Quality, and Care Delivery
In this installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #5, patient engagement and centricity in healthcare decision making.
2023 Top Trends in Health Economics and Outcomes Research
Avalere identified the top trends in health economics and outcomes research in 2023 and beyond. In this video, Avalere experts dive into a few of the key trends in HEOR that are significantly shaping the landscape.
Maximizing Access & Uptake for Digital Health Technologies
Significant investment and attention has been paid to the digital health space in recent years as a promising frontier in improving care for patients. In this video, Avalere experts discuss several solutions, including increased, streamlined stakeholder collaboration, improvements in evidence generation, established value assessment frameworks, and identification of a clear reimbursement pathway that can create a path for more optimal access, uptake, and utilization.
Unpacking the Implications of the Negotiated Drug List, Part 2
In Part 2 of our video series on the negotiated drug list, Avalere experts discuss topics including effectiveness measures that will inform CMS’s maximum fair price determinations, evidence generation strategies for manufacturers with products that have been selected for negotiation, or that are eligible for selection in the future, and CMS’s definition of therapeutic alternatives.
Spotlight on Avalere’s Evidence and Strategy Practice
Laura Housman, Avalere’s Evidence and Strategy Practice Director, discusses her past experience, trends in real-world evidence, and the role of data in advocating for the patient voice.
Part D Redesign’s Impact on Plan-Manufacturer Contracting
Avalere experts discussed how IRA’s Part D redesign may affect plan behavior in Plan Year 2025 and how manufacturers should approach contracting and market access.